ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 190

NLRP3 Gene Analysis for Patients with Schnitzler’s Syndrome

Cong-Qiu Chu1, Carrie R. Austin2, Trudy M. Doyle2, Kelley A. Goodwin2, Noha El Torgomen2, Regina Treudler3 and Tammy M. Martin4, 1Rheumatology, Oregon Health & Science Univ and Portland VA Medical Center, Portland, OR, 2Casey Eye Institute, Oregon Health & Science University, Portland, OR, 3Department of Dermatology, Venereology and Allergology, Universitätsklinikum Leipzig AöR, Leipzig, Germany, 4Ophthalmology/L467AD, Oregon Health & Science Univ, Portland, OR

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: genomics and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Schnitzler’s syndrome is characterized by chronic urticaria, intermittent fever, arthralgia, bone pain, gammopathy and marked systemic inflammation. The striking response to IL-1 blockade suggests that Schnitzler’s syndrome is an IL-1 mediated condition of the expanding spectrum of systemic autoinflammatory disorders. However, the mechanism leading to the increased IL-1 activity has remained elusive. We aim to identify genetic predisposition in patients with Schnitzler’s syndrome.

Methods:

Genomic DNA was extracted from peripheral blood mononuclear cells from 4 patients with a clinical diagnosis of Schnitzler’s syndrome. DNA sequencing was performed in both directions of NLRP3 gene regions, including exon 3 which contains the majority of mutations associated with the cryopyrinopathies. Genetic data of patients was compared with the reference sequence for mutations.

Results:

Of the 4 patients with Schnitzler’s syndrome, 2 had classical findings of monoclonal IgM, kappa; one with polyclonal IgA; and one with polyclonal IgG and IgA. All of the 4 patients were refractory to non-biologic immunosuppressive treatment but achieved sustained clinical remission with daily use of anakinra. DNA sequence analysis of NLRP3 revealed a disease-associated mutation encoding the V198M substitution in the patient with polyclonal IgG and IgA. However, this mutation was not found in the other 3 patients. No other disease-associated mutations were identified in NLRP3 for this patient or in the other 3 patients.

Conclusion:

Genetic studies of Schnitzler’s syndrome have been scanty primarily due to the rarity of the condition and the results have been mixed. Our 4 patients consist of classical (2 cases) and atypical (2 cases) Schnitzler’s syndrome. The V198M mutation was found in one with atypical Schnitzler’s syndrome (polyclonal IgG and IgA). Interestingly, this mutation was previously reported in one patient with classical Schnitzler’s syndrome with monoclonal IgM, kappa (1). However, another genetic study on a patient with classical Schnitzler’s syndrome found no mutations in NLRP3 (2). The distinct feature of Schnitzler’s syndrome is its gammopathy which is poorly responsive to IL-1 blockade suggesting that IL-1 may not mediate the gammopathy. Complete analysis of NLRP3 exons and their flanking regions in this cohort is underway as disease-associated mutations outside of exon 3 have been reported and there may be as yet unknown mutations involved in this phenotype. The presence of an NLRP3 mutation in another patient with Schnitzler’s syndrome confirms the finding that this disorder is inflammasome-mediated.

References:

1. Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol. 2010;125:500-2.

2. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol. 2008;121:260-2.


Disclosure:

C. Q. Chu,
None;

C. R. Austin,
None;

T. M. Doyle,
None;

K. A. Goodwin,
None;

N. El Torgomen,
None;

R. Treudler,
None;

T. M. Martin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nlrp3-gene-analysis-for-patients-with-schnitzlers-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology